Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up.
Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview.
“Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said, adding that developing a...
AI Brief
Your highlights
This article is available on the publisher's site.